EA201391568A1 - Новые производные имидазола, подходящие для лечения артрита - Google Patents

Новые производные имидазола, подходящие для лечения артрита

Info

Publication number
EA201391568A1
EA201391568A1 EA201391568A EA201391568A EA201391568A1 EA 201391568 A1 EA201391568 A1 EA 201391568A1 EA 201391568 A EA201391568 A EA 201391568A EA 201391568 A EA201391568 A EA 201391568A EA 201391568 A1 EA201391568 A1 EA 201391568A1
Authority
EA
Eurasian Patent Office
Prior art keywords
arthritis
treatment
derivatives suitable
imidazol derivatives
new
Prior art date
Application number
EA201391568A
Other languages
English (en)
Inventor
Норман Эрл Хьюэс
Тимоти Эндрю Вудс
Брайан Херст Норман
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201391568A1 publication Critical patent/EA201391568A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88Nitrogen atoms, e.g. allantoin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В изобретении предложены соединения приведенной ниже формулыгде А, X и R1-R6 такие, как описано в настоящей заявке, их фармацевтически приемлемые соли и фармацевтическая композиция, содержащая указанное соединение; способы лечения боли, связанной с остеоартритом с применением одного из указанных соединений или их фармацевтически приемлемых солей, а также способы получения указанных соединений.
EA201391568A 2011-05-26 2012-05-10 Новые производные имидазола, подходящие для лечения артрита EA201391568A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490222P 2011-05-26 2011-05-26
PCT/US2012/037200 WO2012161965A1 (en) 2011-05-26 2012-05-10 Novel imidazole derivatives useful for the treatment of arthritis

Publications (1)

Publication Number Publication Date
EA201391568A1 true EA201391568A1 (ru) 2014-04-30

Family

ID=46148987

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391568A EA201391568A1 (ru) 2011-05-26 2012-05-10 Новые производные имидазола, подходящие для лечения артрита

Country Status (22)

Country Link
US (1) US8648200B2 (ru)
EP (1) EP2714679A1 (ru)
JP (1) JP2014518886A (ru)
KR (1) KR20130143138A (ru)
CN (1) CN103562200A (ru)
AR (1) AR086254A1 (ru)
AU (1) AU2012259234A1 (ru)
BR (1) BR112013029692A2 (ru)
CA (1) CA2836240A1 (ru)
CO (1) CO6811858A2 (ru)
CR (1) CR20130534A (ru)
DO (1) DOP2013000276A (ru)
EA (1) EA201391568A1 (ru)
EC (1) ECSP13013047A (ru)
IL (1) IL229318A0 (ru)
MA (1) MA35128B1 (ru)
MX (1) MX2013013859A (ru)
SG (1) SG195020A1 (ru)
TN (1) TN2013000434A1 (ru)
TW (1) TW201311658A (ru)
WO (1) WO2012161965A1 (ru)
ZA (1) ZA201308609B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871947B2 (en) 2013-02-04 2014-10-28 KingChem LLC Preparation of alkyl 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid ester
CN103467379A (zh) * 2013-08-23 2013-12-25 江苏恒安化工有限公司 3-三氟甲基-1-甲基吡唑-4-甲酸的制备方法
CN103601675B (zh) * 2013-10-08 2015-10-28 南京复兴生物科技有限公司 一种5-氨甲基烟酸的制备方法
CN103483250B (zh) * 2013-10-08 2015-07-22 南京复兴生物科技有限公司 一种5-氨甲基烟酸的制备方法
US9139507B2 (en) 2013-12-09 2015-09-22 KingChem LLC. Process for the preparation of alkyl 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylate and its analogs
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
EP3119394B1 (en) * 2014-03-19 2021-05-12 Curza Global LLC Compositions and methods comprising 2-(acylamino)imidazoles
CN105636951B (zh) 2014-04-14 2018-05-15 上海恒瑞医药有限公司 酰胺类衍生物及其可药用盐、其制备方法及其在医药上的应用
WO2017030115A1 (ja) * 2015-08-17 2017-02-23 日本たばこ産業株式会社 ヒドロキシトリアジン化合物及びその医薬用途
WO2018184019A1 (en) 2017-03-31 2018-10-04 Curza Global, Llc Compositions and methods comprising substituted 2-aminoimidazoles
CN109293567A (zh) * 2018-11-23 2019-02-01 上海睿腾医药科技有限公司 一种5-溴-2-甲基烟酸乙酯的合成方法
EP3983074A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Pyridine carbamates and their use as glun2b receptor modulators
EP3990476A1 (en) 2019-06-25 2022-05-04 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
US11795223B2 (en) 2019-10-18 2023-10-24 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
AU2020374947A1 (en) 2019-10-31 2022-03-31 Forty Seven, Inc. Anti-CD47 and anti-CD20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CN110845426A (zh) * 2019-11-29 2020-02-28 都创(上海)医药科技有限公司 一种2-氯-5-氰基嘧啶化合物制备方法
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
PE20231067A1 (es) 2020-02-14 2023-07-17 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos
MX2022013619A (es) 2020-05-01 2022-11-16 Gilead Sciences Inc Compuestos de 2,4-dioxopirimidina que inhiben cd73.
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
IL309378A (en) 2021-06-23 2024-02-01 Gilead Sciences Inc DIACYLGLYERCOL KINASE MODULATING COMPOUNDS
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240023628A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CN118139858A (zh) 2021-10-28 2024-06-04 吉利德科学公司 吡地嗪-3(2h)-酮衍生物
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ikaros鋅指家族降解劑及其用途
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005295752A1 (en) * 2004-10-15 2006-04-27 Amgen Inc. Imidazole derivatives as vanilloid receptor ligands
WO2009079001A1 (en) * 2007-12-18 2009-06-25 Janssen Pharmaceutica N.V. Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
US20100324086A1 (en) 2008-02-19 2010-12-23 Novasaid Ab Compounds and methods
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2010127152A2 (en) * 2009-04-29 2010-11-04 Irm Llc Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
EP2491007B1 (en) * 2009-10-23 2013-09-25 Boehringer Ingelheim International GmbH Inhibitors of the microsomal prostaglandin E2 synthase-1
AR084174A1 (es) * 2010-12-21 2013-04-24 Lilly Co Eli Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica

Also Published As

Publication number Publication date
IL229318A0 (en) 2014-01-30
AR086254A1 (es) 2013-11-27
SG195020A1 (en) 2013-12-30
ECSP13013047A (es) 2014-01-31
CO6811858A2 (es) 2013-12-16
ZA201308609B (en) 2015-05-27
TN2013000434A1 (en) 2015-03-30
DOP2013000276A (es) 2014-03-31
MX2013013859A (es) 2014-05-28
CR20130534A (es) 2014-03-12
EP2714679A1 (en) 2014-04-09
AU2012259234A1 (en) 2013-11-14
KR20130143138A (ko) 2013-12-30
US20120302608A1 (en) 2012-11-29
JP2014518886A (ja) 2014-08-07
WO2012161965A1 (en) 2012-11-29
CN103562200A (zh) 2014-02-05
US8648200B2 (en) 2014-02-11
TW201311658A (zh) 2013-03-16
BR112013029692A2 (pt) 2017-01-17
MA35128B1 (fr) 2014-05-02
CA2836240A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
EA201391568A1 (ru) Новые производные имидазола, подходящие для лечения артрита
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
CY1119090T1 (el) Δευτεριωμενα παραγωγα ιβακαφτορης
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
EA201690094A1 (ru) Ингибиторы syk
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201891553A1 (ru) Ингибиторы syk
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201490673A1 (ru) Производные пирролопиримидина и пурина
UA111841C2 (uk) Сполуки бензотіазолу та їх фармацевтичне застосування
EA201290632A1 (ru) Производные бетулина
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201391000A1 (ru) Индольные соединения или их аналоги, полезные для лечения возрастной макулярной дегенерации (amd)
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
EA201490650A1 (ru) Фармацевтические композиции
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201101507A1 (ru) Способы лечения солидных опухолей
EA201500544A1 (ru) НОВЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ АГЕНТОВ И ИНГИБИТОРОВ β-ЛАКТАМАЗ
EA201390626A1 (ru) Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций